Effects of Diabetes on pulmonary function tests in COPD Patient
Abstract
COPD (chronic obstructive pulmonary disease) is a condition caused by abnormalities in the inflammatory responses of the lungs to irritable particles or gases. This is an irreversible condition that progresses in later years.Diabetes patients have an increased risk of developing abnormal lung functioning and also in conditions of COPD it even worsens the condition, up to 1.6-16% of the COPD population were affected due to diabetes mellitus.Many studies also suggest that the lungs are a target organ in diabetes and glycemic exposure may be a causation factor for reduced lung function. Systemic inflammation, hypoxemia, oxidative stress, altered gas exchange, and changes in lung tissues were the major impacts on the respiratory system which were induced by hypoglycemia. In this study, we aimed to assess the lung functioning in COPD patients with diabetes by performing the pulmonary functions test like spirometry by obtaining the values of FVC, FEV1, FEV/FVC, and PEF thereby analyzing the level of lung dysfunction that has been done. Patients were includes of both genders and were divided into two groups depending on their disease group 1 includes COPD and group 2 includes COPD with DM considering twenty members in each group. Our study results show that diabetes worsens the lung functioning in COPD than it already is, it may also cause respiratory collapse if untreated.
References
2. Anuradha Y, Saxena AK, Kusum G, Poonam P, Meena G. Study of Pulmonary Function Tests in Type 2 Diabetes Mellitus: Case-Control Study, IOSR Journal of Dental and Medical Sciences. 2013 Oct; 10:74-77.
3. Rogliani P, Luca G. Lauro D. Chronic obstructive pulmonary disease and diabetes. COPD Res Pract. 2015 Aug; 1(3):933-940.
4. Supriya A, Narmadha MP, Anjali RM, Varghese PR, Impact of Diabetes Mellitus on Pulmonary Function Tests in COPD Patients, Int J Contemp Med Res. 2017 April; 4(4):795-797.
5. Raghuveer R, Gopal V. A Comparison of Polyherbal Tablets to Treat Type II Diabetes. Future J. Pharm. Health Sci. 2021 Mar; 1(2):8-11.
6. Kozhevnikova SA, Budnevskiy AV, Ovsyannikov ES, Malysh EY, Belov VN. Chronic obstructive pulmonary disease and diabetes: a look at the epidemiology, pathogenetic mechanisms, treatment. Patol Fiziol Eksp Ter. 2016 Oct-Dec; 60(4):122-7.
7. Mekov EV, Slavova YG, Genova MP, Tsakova AD, Kostadinov DT, Minchev DD, Marinova DM, Boyanov MA. Diabetes mellitus type 2 in hospitalized COPD patients: impact on quality of life and lung function. Folia Medica 2016 April; 58(1): 36-41.
8. Zaman SU, Banerjee J, Singhamahapatra A, Dey PK, Roy A, Roy K, Roy Basu K. Assessment of lung function by spirometry and diffusion study and effect of glycemic control on pulmonary function in type 2 diabetes mellitus patients of the eastern India. J Clin Diagn Res. 2014 Nov; 8(11):BC01-4.
9. Huang H, Guo Q, Li L, Lin S, Lin Y, Gong X, Yao J, Liang J, Lin L, Wen J, Chen G. Effect of type 2 diabetes mellitus on pulmonary function. Exp Clin Endocrinol Diabetes. 2014 Jun; 122(6):322-6.
10. Ho TW, Huang CT, Ruan SY, Tsai YJ, Lai F, Yu CJ. Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality. PLoS One. 2017 Apr 14; 12(4):e0175794.
11. Shah SH, Sonawane P, Nahar P, Vaidya S, Salvi S. Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. Lung India. 2013 Apr; 30(2):108-12.
12. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2004 Mar; 27(3):752-7.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Innovative Science & Technology affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJIST.
Download link for COPYRIGHT FORM
